#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2.
1-1	0-2	2.	_	_	_	_

#Text=Typical Ligands for Bile Acids
2-1	3-10	Typical	substance[1]	new[1]	_	_
2-2	11-18	Ligands	substance[1]	new[1]	_	_
2-3	19-22	for	substance[1]	new[1]	_	_
2-4	23-27	Bile	substance[1]|object|substance[3]	new[1]|new|new[3]	ana|coref	3-7[0_3]|15-5
2-5	28-33	Acids	substance[1]|substance[3]	new[1]|new[3]	_	_

#Text=BA targeted therapy is based on their receptors and ligands .
3-1	34-36	BA	person	new	coref	7-4[39_0]
3-2	37-45	targeted	_	_	_	_
3-3	46-53	therapy	abstract	new	_	_
3-4	54-56	is	_	_	_	_
3-5	57-62	based	_	_	_	_
3-6	63-65	on	_	_	_	_
3-7	66-71	their	substance|substance[7]	giv|new[7]	coref	4-14[14_7]
3-8	72-81	receptors	substance[7]	new[7]	_	_
3-9	82-85	and	_	_	_	_
3-10	86-93	ligands	abstract	new	_	_
3-11	94-95	.	_	_	_	_

#Text=The regulation of BAs on other pathways occurs mainly through the activation of nuclear hormone receptors ( NHRs ) such as the farnesoid X receptor ( FXR ) , pregnane X receptor ( PXR ) , and vitamin D receptor ( VDR ) .
4-1	96-99	The	abstract[9]	new[9]	_	_
4-2	100-110	regulation	abstract[9]	new[9]	_	_
4-3	111-113	of	abstract[9]	new[9]	_	_
4-4	114-117	BAs	abstract[9]|abstract[10]	new[9]|new[10]	coref	7-1[38_10]
4-5	118-120	on	abstract[9]|abstract[10]	new[9]|new[10]	_	_
4-6	121-126	other	abstract[9]|abstract[10]|abstract[11]	new[9]|new[10]|new[11]	_	_
4-7	127-135	pathways	abstract[9]|abstract[10]|abstract[11]	new[9]|new[10]|new[11]	_	_
4-8	136-142	occurs	_	_	_	_
4-9	143-149	mainly	_	_	_	_
4-10	150-157	through	_	_	_	_
4-11	158-161	the	event[12]	new[12]	_	_
4-12	162-172	activation	event[12]	new[12]	_	_
4-13	173-175	of	event[12]	new[12]	_	_
4-14	176-183	nuclear	event[12]|abstract[14]	new[12]|giv[14]	appos	4-18[0_14]
4-15	184-191	hormone	event[12]|substance|abstract[14]	new[12]|new|giv[14]	coref	6-12
4-16	192-201	receptors	event[12]|abstract[14]	new[12]|giv[14]	_	_
4-17	202-203	(	event[12]	new[12]	_	_
4-18	204-208	NHRs	event[12]|abstract	new[12]|giv	coref	5-5[23_0]
4-19	209-210	)	event[12]	new[12]	_	_
4-20	211-215	such	event[12]	new[12]	_	_
4-21	216-218	as	event[12]	new[12]	_	_
4-22	219-222	the	event[12]|object[16]	new[12]|new[16]	_	_
4-23	223-232	farnesoid	event[12]|object[16]	new[12]|new[16]	_	_
4-24	233-234	X	event[12]|object[16]	new[12]|new[16]	_	_
4-25	235-243	receptor	event[12]|object[16]	new[12]|new[16]	_	_
4-26	244-245	(	_	_	_	_
4-27	246-249	FXR	object	new	coref	7-14
4-28	250-251	)	_	_	_	_
4-29	252-253	,	_	_	_	_
4-30	254-262	pregnane	object	new	_	_
4-31	263-264	X	_	_	_	_
4-32	265-273	receptor	_	_	_	_
4-33	274-275	(	_	_	_	_
4-34	276-279	PXR	_	_	_	_
4-35	280-281	)	_	_	_	_
4-36	282-283	,	_	_	_	_
4-37	284-287	and	_	_	_	_
4-38	288-295	vitamin	substance	new	_	_
4-39	296-297	D	person	new	_	_
4-40	298-306	receptor	_	_	_	_
4-41	307-308	(	_	_	_	_
4-42	309-312	VDR	abstract	new	_	_
4-43	313-314	)	_	_	_	_
4-44	315-316	.	_	_	_	_

#Text=For the activation of these receptors , it is necessary that they interact with the retinoid X receptor as a heterodimer ( RXR ) .
5-1	317-320	For	_	_	_	_
5-2	321-324	the	event[22]	new[22]	coref	15-10[79_22]
5-3	325-335	activation	event[22]	new[22]	_	_
5-4	336-338	of	event[22]	new[22]	_	_
5-5	339-344	these	event[22]|substance[23]	new[22]|giv[23]	ana	5-12[0_23]
5-6	345-354	receptors	event[22]|substance[23]	new[22]|giv[23]	_	_
5-7	355-356	,	_	_	_	_
5-8	357-359	it	abstract	new	cata	5-8[0_26]
5-9	360-362	is	_	_	_	_
5-10	363-372	necessary	_	_	_	_
5-11	373-377	that	abstract[26]	new[26]	_	_
5-12	378-382	they	substance|abstract[26]	giv|new[26]	ana	6-3
5-13	383-391	interact	abstract[26]	new[26]	_	_
5-14	392-396	with	_	_	_	_
5-15	397-400	the	object[27]	new[27]	_	_
5-16	401-409	retinoid	object[27]	new[27]	_	_
5-17	410-411	X	object[27]	new[27]	_	_
5-18	412-420	receptor	object[27]|substance	new[27]|new	coref	16-29[91_0]
5-19	421-423	as	_	_	_	_
5-20	424-425	a	_	_	_	_
5-21	426-437	heterodimer	_	_	_	_
5-22	438-439	(	_	_	_	_
5-23	440-443	RXR	abstract	new	_	_
5-24	444-445	)	_	_	_	_
5-25	446-447	.	_	_	_	_

#Text=Afterwards , they act on various regulatory regions by binding to hormone response elements causing several genes to be up or downregulated in their transcription .
6-1	448-458	Afterwards	_	_	_	_
6-2	459-460	,	_	_	_	_
6-3	461-465	they	abstract	giv	_	_
6-4	466-469	act	_	_	_	_
6-5	470-472	on	_	_	_	_
6-6	473-480	various	place[31]	new[31]	_	_
6-7	481-491	regulatory	place[31]	new[31]	_	_
6-8	492-499	regions	place[31]	new[31]	_	_
6-9	500-502	by	_	_	_	_
6-10	503-510	binding	_	_	_	_
6-11	511-513	to	_	_	_	_
6-12	514-521	hormone	substance|abstract[34]	giv|new[34]	_	_
6-13	522-530	response	abstract|abstract[34]	new|new[34]	_	_
6-14	531-539	elements	abstract[34]	new[34]	_	_
6-15	540-547	causing	_	_	_	_
6-16	548-555	several	abstract[35]	new[35]	ana	6-24[0_35]
6-17	556-561	genes	abstract[35]	new[35]	_	_
6-18	562-564	to	_	_	_	_
6-19	565-567	be	_	_	_	_
6-20	568-570	up	_	_	_	_
6-21	571-573	or	_	_	_	_
6-22	574-587	downregulated	_	_	_	_
6-23	588-590	in	_	_	_	_
6-24	591-596	their	abstract|abstract[37]	giv|new[37]	_	_
6-25	597-610	transcription	abstract[37]	new[37]	_	_
6-26	611-612	.	_	_	_	_

#Text=Most BAs and the secondary BA , and LCA , are binding to FXR and PXR respectively .
7-1	613-617	Most	abstract[38]	giv[38]	coref	14-8[0_38]
7-2	618-621	BAs	abstract[38]	giv[38]	_	_
7-3	622-625	and	_	_	_	_
7-4	626-629	the	person[39]	giv[39]	coref	10-7[0_39]
7-5	630-639	secondary	person[39]	giv[39]	_	_
7-6	640-642	BA	person[39]	giv[39]	_	_
7-7	643-644	,	_	_	_	_
7-8	645-648	and	_	_	_	_
7-9	649-652	LCA	substance	new	coref	12-14
7-10	653-654	,	_	_	_	_
7-11	655-658	are	_	_	_	_
7-12	659-666	binding	_	_	_	_
7-13	667-669	to	_	_	_	_
7-14	670-673	FXR	abstract	giv	coref	9-1
7-15	674-677	and	_	_	_	_
7-16	678-681	PXR	abstract	new	_	_
7-17	682-694	respectively	_	_	_	_
7-18	695-696	.	_	_	_	_

#Text=2.1 .
8-1	697-700	2.1	abstract	new	_	_
8-2	701-702	.	_	_	_	_

#Text=FXR
9-1	703-706	FXR	abstract	giv	coref	10-1

#Text=FXR plays an important role in BA , glucose , and lipid metabolism .
10-1	707-710	FXR	abstract	giv	coref	13-11
10-2	711-716	plays	_	_	_	_
10-3	717-719	an	abstract[46]	new[46]	coref	25-10[141_46]
10-4	720-729	important	abstract[46]	new[46]	_	_
10-5	730-734	role	abstract[46]	new[46]	_	_
10-6	735-737	in	abstract[46]	new[46]	_	_
10-7	738-740	BA	abstract[46]|person	new[46]|giv	coref	16-5[80_0]
10-8	741-742	,	abstract[46]	new[46]	_	_
10-9	743-750	glucose	abstract[46]|substance	new[46]|new	coref	19-19
10-10	751-752	,	abstract[46]	new[46]	_	_
10-11	753-756	and	abstract[46]	new[46]	_	_
10-12	757-762	lipid	abstract[46]|object|abstract[50]	new[46]|new|new[50]	ana|coref	11-1[0_50]|20-13
10-13	763-773	metabolism	abstract[46]|abstract[50]	new[46]|new[50]	_	_
10-14	774-775	.	_	_	_	_

#Text=It is most highly expressed in the liver , ileum , kidneys , and adrenal glands .
11-1	776-778	It	abstract	giv	coref	19-18[104_0]
11-2	779-781	is	_	_	_	_
11-3	782-786	most	_	_	_	_
11-4	787-793	highly	_	_	_	_
11-5	794-803	expressed	_	_	_	_
11-6	804-806	in	_	_	_	_
11-7	807-810	the	object[52]	new[52]	coref	15-2[75_52]
11-8	811-816	liver	object[52]	new[52]	_	_
11-9	817-818	,	_	_	_	_
11-10	819-824	ileum	place	new	coref	16-7[81_0]
11-11	825-826	,	_	_	_	_
11-12	827-834	kidneys	place	new	_	_
11-13	835-836	,	_	_	_	_
11-14	837-840	and	_	_	_	_
11-15	841-848	adrenal	abstract|object[56]	new|new[56]	_	_
11-16	849-855	glands	object[56]	new[56]	_	_
11-17	856-857	.	_	_	_	_

#Text=The strongest activator is CDCA , followed by DCA , CA , and LCA .
12-1	858-861	The	object[57]	new[57]	coref	12-5[0_57]
12-2	862-871	strongest	object[57]	new[57]	_	_
12-3	872-881	activator	object[57]	new[57]	_	_
12-4	882-884	is	_	_	_	_
12-5	885-889	CDCA	object	giv	coref	32-6[177_0]
12-6	890-891	,	_	_	_	_
12-7	892-900	followed	_	_	_	_
12-8	901-903	by	_	_	_	_
12-9	904-907	DCA	abstract	new	_	_
12-10	908-909	,	_	_	_	_
12-11	910-912	CA	abstract	new	_	_
12-12	913-914	,	_	_	_	_
12-13	915-918	and	_	_	_	_
12-14	919-922	LCA	abstract	giv	coref	13-5
12-15	923-924	.	_	_	_	_

#Text=Despite the fact that LCA is a weak activator of FXR , it is a very strong downregulator of its function and thus could be termed a partial agonist .
13-1	925-932	Despite	_	_	_	_
13-2	933-936	the	abstract[62]	new[62]	_	_
13-3	937-941	fact	abstract[62]	new[62]	_	_
13-4	942-946	that	abstract[62]	new[62]	_	_
13-5	947-950	LCA	abstract[62]|abstract	new[62]|giv	coref	13-7[64_0]
13-6	951-953	is	abstract[62]	new[62]	_	_
13-7	954-955	a	abstract[62]|abstract[64]	new[62]|giv[64]	coref	32-1[0_64]
13-8	956-960	weak	abstract[62]|abstract[64]	new[62]|giv[64]	_	_
13-9	961-970	activator	abstract[62]|abstract[64]	new[62]|giv[64]	_	_
13-10	971-973	of	abstract[62]|abstract[64]	new[62]|giv[64]	_	_
13-11	974-977	FXR	abstract[62]|abstract[64]|abstract	new[62]|giv[64]|giv	ana	13-13
13-12	978-979	,	_	_	_	_
13-13	980-982	it	abstract	giv	coref	13-15[67_0]
13-14	983-985	is	_	_	_	_
13-15	986-987	a	abstract[67]	giv[67]	coref	14-15[0_67]
13-16	988-992	very	abstract[67]	giv[67]	_	_
13-17	993-999	strong	abstract[67]	giv[67]	_	_
13-18	1000-1013	downregulator	abstract[67]	giv[67]	_	_
13-19	1014-1016	of	abstract[67]	giv[67]	_	_
13-20	1017-1020	its	abstract[67]|abstract[68]	giv[67]|new[68]	coref	14-11[73_68]
13-21	1021-1029	function	abstract[67]|abstract[68]	giv[67]|new[68]	_	_
13-22	1030-1033	and	_	_	_	_
13-23	1034-1038	thus	_	_	_	_
13-24	1039-1044	could	_	_	_	_
13-25	1045-1047	be	_	_	_	_
13-26	1048-1054	termed	_	_	_	_
13-27	1055-1056	a	abstract[69]	new[69]	_	_
13-28	1057-1064	partial	abstract[69]	new[69]	_	_
13-29	1065-1072	agonist	abstract[69]	new[69]	_	_
13-30	1073-1074	.	_	_	_	_

#Text=Controlling the synthesis and enterohepatic circulation of BAs , represents the major function of FXR .
14-1	1075-1086	Controlling	_	_	_	_
14-2	1087-1090	the	abstract[70]	new[70]	coref	19-24[106_70]
14-3	1091-1100	synthesis	abstract[70]	new[70]	_	_
14-4	1101-1104	and	_	_	_	_
14-5	1105-1118	enterohepatic	abstract[71]	new[71]	_	_
14-6	1119-1130	circulation	abstract[71]	new[71]	_	_
14-7	1131-1133	of	abstract[71]	new[71]	_	_
14-8	1134-1137	BAs	abstract[71]|abstract	new[71]|giv	coref	26-6
14-9	1138-1139	,	_	_	_	_
14-10	1140-1150	represents	_	_	_	_
14-11	1151-1154	the	abstract[73]	giv[73]	_	_
14-12	1155-1160	major	abstract[73]	giv[73]	_	_
14-13	1161-1169	function	abstract[73]	giv[73]	_	_
14-14	1170-1172	of	abstract[73]	giv[73]	_	_
14-15	1173-1176	FXR	abstract[73]|abstract	giv[73]|giv	coref	15-10
14-16	1177-1178	.	_	_	_	_

#Text=In the liver , bile flow is prompted through FXR activation .
15-1	1179-1181	In	_	_	_	_
15-2	1182-1185	the	object[75]	giv[75]	coref	21-7[0_75]
15-3	1186-1191	liver	object[75]	giv[75]	_	_
15-4	1192-1193	,	_	_	_	_
15-5	1194-1198	bile	object|abstract[77]	giv|new[77]	_	_
15-6	1199-1203	flow	abstract[77]	new[77]	_	_
15-7	1204-1206	is	_	_	_	_
15-8	1207-1215	prompted	_	_	_	_
15-9	1216-1223	through	_	_	_	_
15-10	1224-1227	FXR	object|event[79]	giv|giv[79]	coref	24-7[139_0]
15-11	1228-1238	activation	event[79]	giv[79]	_	_
15-12	1239-1240	.	_	_	_	_

#Text=After being activated through BA in the ileum , the expression of fibroblast growth factor 15/19 ( FGF15/19 ) increases , leading to an activation of fibroblast growth factor receptor 4 ( FGFR4 ) in hepatocytes (
16-1	1241-1246	After	_	_	_	_
16-2	1247-1252	being	_	_	_	_
16-3	1253-1262	activated	_	_	_	_
16-4	1263-1270	through	_	_	_	_
16-5	1271-1273	BA	person[80]	giv[80]	coref	19-14[0_80]
16-6	1274-1276	in	person[80]	giv[80]	_	_
16-7	1277-1280	the	person[80]|place[81]	giv[80]|giv[81]	coref	33-15[0_81]
16-8	1281-1286	ileum	person[80]|place[81]	giv[80]|giv[81]	_	_
16-9	1287-1288	,	_	_	_	_
16-10	1289-1292	the	abstract[82]	new[82]	_	_
16-11	1293-1303	expression	abstract[82]	new[82]	_	_
16-12	1304-1306	of	abstract[82]	new[82]	_	_
16-13	1307-1317	fibroblast	abstract[82]|event|abstract[85]	new[82]|new|new[85]	coref|coref	16-27|16-29[0_85]
16-14	1318-1324	growth	abstract[82]|abstract|abstract[85]	new[82]|new|new[85]	coref	16-27[89_0]
16-15	1325-1331	factor	abstract[82]|abstract[85]	new[82]|new[85]	_	_
16-16	1332-1337	15/19	abstract[82]|abstract[85]	new[82]|new[85]	_	_
16-17	1338-1339	(	_	_	_	_
16-18	1340-1348	FGF15/19	time	new	coref	19-7
16-19	1349-1350	)	_	_	_	_
16-20	1351-1360	increases	_	_	_	_
16-21	1361-1362	,	_	_	_	_
16-22	1363-1370	leading	_	_	_	_
16-23	1371-1373	to	_	_	_	_
16-24	1374-1376	an	event[87]	new[87]	_	_
16-25	1377-1387	activation	event[87]	new[87]	_	_
16-26	1388-1390	of	event[87]	new[87]	_	_
16-27	1391-1401	fibroblast	event[87]|event|abstract[89]	new[87]|giv|giv[89]	_	_
16-28	1402-1408	growth	event[87]|abstract[89]	new[87]|giv[89]	_	_
16-29	1409-1415	factor	abstract|substance[91]|time[92]	giv|giv[91]|new[92]	coref|coref	28-8[161_91]|35-19
16-30	1416-1424	receptor	substance[91]|time[92]	giv[91]|new[92]	_	_
16-31	1425-1426	4	time[92]	new[92]	_	_
16-32	1427-1428	(	_	_	_	_
16-33	1429-1434	FGFR4	abstract	new	coref	23-4[131_0]
16-34	1435-1436	)	_	_	_	_
16-35	1437-1439	in	_	_	_	_
16-36	1440-1451	hepatocytes	place	new	coref	33-23[186_0]
16-37	1452-1453	(	_	_	_	_

#Text=Figure 1
17-1	1454-1460	Figure	object[95]	new[95]	ana	19-1[0_95]
17-2	1461-1462	1	object[95]	new[95]	_	_

#Text=) .
18-1	1463-1464	)	_	_	_	_
18-2	1465-1466	.	_	_	_	_

#Text=This is of great importance as FGF15/19 is an ileum-derived enterokine that governs BA homeostasis , regulates hepatic glucose metabolism , and stimulates protein synthesis .
19-1	1467-1471	This	object	giv	_	_
19-2	1472-1474	is	_	_	_	_
19-3	1475-1477	of	_	_	_	_
19-4	1478-1483	great	abstract[97]	new[97]	_	_
19-5	1484-1494	importance	abstract[97]	new[97]	_	_
19-6	1495-1497	as	_	_	_	_
19-7	1498-1506	FGF15/19	abstract	giv	coref	19-9[99_0]
19-8	1507-1509	is	_	_	_	_
19-9	1510-1512	an	abstract[99]	giv[99]	_	_
19-10	1513-1526	ileum-derived	abstract[99]	giv[99]	_	_
19-11	1527-1537	enterokine	abstract[99]	giv[99]	_	_
19-12	1538-1542	that	_	_	_	_
19-13	1543-1550	governs	_	_	_	_
19-14	1551-1553	BA	person|abstract[101]	giv|new[101]	coref|coref	27-3[154_101]|34-5
19-15	1554-1565	homeostasis	abstract[101]	new[101]	_	_
19-16	1566-1567	,	_	_	_	_
19-17	1568-1577	regulates	_	_	_	_
19-18	1578-1585	hepatic	object|abstract[104]	new|giv[104]	coref|coref	22-9|28-15[165_104]
19-19	1586-1593	glucose	substance|abstract[104]	giv|giv[104]	coref	34-7
19-20	1594-1604	metabolism	abstract[104]	giv[104]	_	_
19-21	1605-1606	,	_	_	_	_
19-22	1607-1610	and	_	_	_	_
19-23	1611-1621	stimulates	_	_	_	_
19-24	1622-1629	protein	substance|abstract[106]	new|giv[106]	coref	26-9[149_106]
19-25	1630-1639	synthesis	abstract[106]	giv[106]	_	_
19-26	1640-1641	.	_	_	_	_

#Text=If administered pharmacologically or expressed transgenically in mice , FGF19 increases hepatic lipid oxidation , reduces lipogenesis and protects from hepatosteatosis .
20-1	1642-1644	If	_	_	_	_
20-2	1645-1657	administered	_	_	_	_
20-3	1658-1675	pharmacologically	_	_	_	_
20-4	1676-1678	or	_	_	_	_
20-5	1679-1688	expressed	_	_	_	_
20-6	1689-1703	transgenically	_	_	_	_
20-7	1704-1706	in	_	_	_	_
20-8	1707-1711	mice	animal	new	coref	22-26
20-9	1712-1713	,	_	_	_	_
20-10	1714-1719	FGF19	abstract	new	_	_
20-11	1720-1729	increases	_	_	_	_
20-12	1730-1737	hepatic	abstract[110]	new[110]	_	_
20-13	1738-1743	lipid	person|abstract[110]	giv|new[110]	coref	27-5
20-14	1744-1753	oxidation	abstract[110]	new[110]	_	_
20-15	1754-1755	,	_	_	_	_
20-16	1756-1763	reduces	_	_	_	_
20-17	1764-1775	lipogenesis	substance	new	_	_
20-18	1776-1779	and	_	_	_	_
20-19	1780-1788	protects	_	_	_	_
20-20	1789-1793	from	_	_	_	_
20-21	1794-1809	hepatosteatosis	abstract	new	_	_
20-22	1810-1811	.	_	_	_	_

#Text=A lack of it causes impaired liver regeneration .
21-1	1812-1813	A	abstract[113]	new[113]	_	_
21-2	1814-1818	lack	abstract[113]	new[113]	_	_
21-3	1819-1821	of	abstract[113]	new[113]	_	_
21-4	1822-1824	it	abstract[113]	new[113]	_	_
21-5	1825-1831	causes	_	_	_	_
21-6	1832-1840	impaired	abstract[115]	new[115]	_	_
21-7	1841-1846	liver	object|abstract[115]	giv|new[115]	coref	22-23[126_0]
21-8	1847-1859	regeneration	abstract[115]	new[115]	_	_
21-9	1860-1861	.	_	_	_	_

#Text=A lack of FGF 15 results in increased hepatic steatosis and in the development of endoplasmic reticulum ( ER ) stress in the liver of mice fed a high fat diet .
22-1	1862-1863	A	abstract[116]	new[116]	_	_
22-2	1864-1868	lack	abstract[116]	new[116]	_	_
22-3	1869-1871	of	abstract[116]	new[116]	_	_
22-4	1872-1875	FGF	abstract[116]|event|abstract[118]	new[116]|new|new[118]	_	_
22-5	1876-1878	15	abstract[116]|abstract[118]	new[116]|new[118]	_	_
22-6	1879-1886	results	abstract[116]|abstract[118]	new[116]|new[118]	_	_
22-7	1887-1889	in	abstract[116]|abstract[118]	new[116]|new[118]	_	_
22-8	1890-1899	increased	abstract[116]|abstract[118]|abstract[120]	new[116]|new[118]|new[120]	coref	36-24[229_120]
22-9	1900-1907	hepatic	abstract[116]|abstract[118]|abstract|abstract[120]	new[116]|new[118]|giv|new[120]	coref	27-4
22-10	1908-1917	steatosis	abstract[116]|abstract[118]|abstract[120]	new[116]|new[118]|new[120]	_	_
22-11	1918-1921	and	_	_	_	_
22-12	1922-1924	in	_	_	_	_
22-13	1925-1928	the	abstract[121]	new[121]	_	_
22-14	1929-1940	development	abstract[121]	new[121]	_	_
22-15	1941-1943	of	abstract[121]	new[121]	_	_
22-16	1944-1955	endoplasmic	abstract[121]|abstract|object[123]	new[121]|new|new[123]	_	_
22-17	1956-1965	reticulum	abstract[121]|object[123]	new[121]|new[123]	_	_
22-18	1966-1967	(	_	_	_	_
22-19	1968-1970	ER	person	new	_	_
22-20	1971-1972	)	_	_	_	_
22-21	1973-1979	stress	abstract[125]	new[125]	_	_
22-22	1980-1982	in	abstract[125]	new[125]	_	_
22-23	1983-1986	the	abstract[125]|object[126]	new[125]|giv[126]	coref	23-17[136_126]
22-24	1987-1992	liver	abstract[125]|object[126]	new[125]|giv[126]	_	_
22-25	1993-1995	of	abstract[125]|object[126]	new[125]|giv[126]	_	_
22-26	1996-2000	mice	abstract[125]|object[126]|animal	new[125]|giv[126]|giv	coref	36-5[223_0]
22-27	2001-2004	fed	_	_	_	_
22-28	2005-2006	a	substance[129]	new[129]	_	_
22-29	2007-2011	high	substance[129]	new[129]	_	_
22-30	2012-2015	fat	substance|substance[129]	new|new[129]	_	_
22-31	2016-2020	diet	substance[129]	new[129]	_	_
22-32	2021-2022	.	_	_	_	_

#Text=The activation of FGFR4 together with the activation of small heterodimer partner ( SHP ) in the liver , inhibits CYP7A1 .
23-1	2023-2026	The	abstract[130]	new[130]	_	_
23-2	2027-2037	activation	abstract[130]	new[130]	_	_
23-3	2038-2040	of	abstract[130]	new[130]	_	_
23-4	2041-2046	FGFR4	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
23-5	2047-2055	together	abstract[130]|abstract[131]	new[130]|giv[131]	_	_
23-6	2056-2060	with	abstract[130]	new[130]	_	_
23-7	2061-2064	the	abstract[130]|abstract[132]	new[130]|new[132]	_	_
23-8	2065-2075	activation	abstract[130]|abstract[132]	new[130]|new[132]	_	_
23-9	2076-2078	of	abstract[130]|abstract[132]	new[130]|new[132]	_	_
23-10	2079-2084	small	abstract[130]|abstract[132]|person[134]	new[130]|new[132]|new[134]	appos	23-14[0_134]
23-11	2085-2096	heterodimer	abstract[130]|abstract[132]|object|person[134]	new[130]|new[132]|new|new[134]	_	_
23-12	2097-2104	partner	abstract[130]|abstract[132]|person[134]	new[130]|new[132]|new[134]	_	_
23-13	2105-2106	(	_	_	_	_
23-14	2107-2110	SHP	person	giv	_	_
23-15	2111-2112	)	_	_	_	_
23-16	2113-2115	in	_	_	_	_
23-17	2116-2119	the	object[136]	giv[136]	coref	33-19[185_136]
23-18	2120-2125	liver	object[136]	giv[136]	_	_
23-19	2126-2127	,	_	_	_	_
23-20	2128-2136	inhibits	_	_	_	_
23-21	2137-2143	CYP7A1	abstract	new	coref	24-5
23-22	2144-2145	.	_	_	_	_

#Text=In order to downregulate CYP7A1 , intestinal-specific FXR is required .
24-1	2146-2148	In	_	_	_	_
24-2	2149-2154	order	_	_	_	_
24-3	2155-2157	to	_	_	_	_
24-4	2158-2170	downregulate	_	_	_	_
24-5	2171-2177	CYP7A1	abstract	giv	_	_
24-6	2178-2179	,	_	_	_	_
24-7	2180-2199	intestinal-specific	object[139]	giv[139]	coref	25-6[140_139]
24-8	2200-2203	FXR	object[139]	giv[139]	_	_
24-9	2204-2206	is	_	_	_	_
24-10	2207-2215	required	_	_	_	_
24-11	2216-2217	.	_	_	_	_

#Text=On the other hand , the liver-specific FXR plays an important role in the repression of the expression of CYP8B1 .
25-1	2218-2220	On	_	_	_	_
25-2	2221-2224	the	_	_	_	_
25-3	2225-2230	other	_	_	_	_
25-4	2231-2235	hand	_	_	_	_
25-5	2236-2237	,	_	_	_	_
25-6	2238-2241	the	object[140]	giv[140]	coref	26-14[0_140]
25-7	2242-2256	liver-specific	object[140]	giv[140]	_	_
25-8	2257-2260	FXR	object[140]	giv[140]	_	_
25-9	2261-2266	plays	_	_	_	_
25-10	2267-2269	an	abstract[141]	giv[141]	coref	34-18[197_141]
25-11	2270-2279	important	abstract[141]	giv[141]	_	_
25-12	2280-2284	role	abstract[141]	giv[141]	_	_
25-13	2285-2287	in	abstract[141]	giv[141]	_	_
25-14	2288-2291	the	abstract[141]|event[142]	giv[141]|new[142]	_	_
25-15	2292-2302	repression	abstract[141]|event[142]	giv[141]|new[142]	_	_
25-16	2303-2305	of	abstract[141]|event[142]	giv[141]|new[142]	_	_
25-17	2306-2309	the	abstract[141]|event[142]|abstract[143]	giv[141]|new[142]|new[143]	_	_
25-18	2310-2320	expression	abstract[141]|event[142]|abstract[143]	giv[141]|new[142]|new[143]	_	_
25-19	2321-2323	of	abstract[141]|event[142]|abstract[143]	giv[141]|new[142]|new[143]	_	_
25-20	2324-2330	CYP8B1	abstract[141]|event[142]|abstract[143]|abstract	giv[141]|new[142]|new[143]|new	_	_
25-21	2331-2332	.	_	_	_	_

#Text=One of the mechanisms for BAs to suppress their own synthesis is through FXR .
26-1	2333-2336	One	object[145]	new[145]	_	_
26-2	2337-2339	of	object[145]	new[145]	_	_
26-3	2340-2343	the	object[145]|abstract[146]	new[145]|new[146]	ana	26-9[0_146]
26-4	2344-2354	mechanisms	object[145]|abstract[146]	new[145]|new[146]	_	_
26-5	2355-2358	for	object[145]|abstract[146]	new[145]|new[146]	_	_
26-6	2359-2362	BAs	object[145]|abstract[146]|substance	new[145]|new[146]|giv	coref	31-9
26-7	2363-2365	to	_	_	_	_
26-8	2366-2374	suppress	_	_	_	_
26-9	2375-2380	their	abstract|abstract[149]	giv|giv[149]	_	_
26-10	2381-2384	own	abstract[149]	giv[149]	_	_
26-11	2385-2394	synthesis	abstract[149]	giv[149]	_	_
26-12	2395-2397	is	_	_	_	_
26-13	2398-2405	through	_	_	_	_
26-14	2406-2409	FXR	abstract	giv	coref	27-1
26-15	2410-2411	.	_	_	_	_

#Text=FXR influences the hepatic lipid homeostasis via SHP , which reduces the expression of SREBP1 .
27-1	2412-2415	FXR	abstract	giv	_	_
27-2	2416-2426	influences	_	_	_	_
27-3	2427-2430	the	abstract[154]	giv[154]	_	_
27-4	2431-2438	hepatic	abstract|abstract[154]	giv|giv[154]	coref	36-24
27-5	2439-2444	lipid	person|abstract[154]	giv|giv[154]	coref	34-10
27-6	2445-2456	homeostasis	abstract[154]	giv[154]	_	_
27-7	2457-2460	via	abstract[154]	giv[154]	_	_
27-8	2461-2464	SHP	abstract[154]|abstract	giv[154]|new	_	_
27-9	2465-2466	,	_	_	_	_
27-10	2467-2472	which	_	_	_	_
27-11	2473-2480	reduces	_	_	_	_
27-12	2481-2484	the	abstract[156]	new[156]	_	_
27-13	2485-2495	expression	abstract[156]	new[156]	_	_
27-14	2496-2498	of	abstract[156]	new[156]	_	_
27-15	2499-2505	SREBP1	abstract[156]|abstract	new[156]|new	ana	28-1
27-16	2506-2507	.	_	_	_	_

#Text=It also regulates the expression of peroxisome proliferator-activated receptor PPAR-α , a regulator of triglyceride metabolism , that can induce free fatty acid β-oxidation .
28-1	2508-2510	It	abstract	giv	_	_
28-2	2511-2515	also	_	_	_	_
28-3	2516-2525	regulates	_	_	_	_
28-4	2526-2529	the	abstract[159]	new[159]	appos	28-8[162_159]
28-5	2530-2540	expression	abstract[159]	new[159]	_	_
28-6	2541-2543	of	abstract[159]	new[159]	_	_
28-7	2544-2554	peroxisome	abstract[159]|abstract	new[159]|new	_	_
28-8	2555-2577	proliferator-activated	substance[161]|substance[162]	giv[161]|giv[162]	appos|coref	28-12[163_162]|30-3[170_161]
28-9	2578-2586	receptor	substance[161]|substance[162]	giv[161]|giv[162]	_	_
28-10	2587-2593	PPAR-α	substance[162]	giv[162]	_	_
28-11	2594-2595	,	_	_	_	_
28-12	2596-2597	a	substance[163]	giv[163]	coref	34-25[200_163]
28-13	2598-2607	regulator	substance[163]	giv[163]	_	_
28-14	2608-2610	of	substance[163]	giv[163]	_	_
28-15	2611-2623	triglyceride	substance[163]|object|abstract[165]	giv[163]|new|giv[165]	coref	34-10[195_165]
28-16	2624-2634	metabolism	substance[163]|abstract[165]	giv[163]|giv[165]	_	_
28-17	2635-2636	,	_	_	_	_
28-18	2637-2641	that	_	_	_	_
28-19	2642-2645	can	_	_	_	_
28-20	2646-2652	induce	_	_	_	_
28-21	2653-2657	free	substance[167]	new[167]	_	_
28-22	2658-2663	fatty	substance[167]	new[167]	_	_
28-23	2664-2668	acid	substance|substance[167]	new|new[167]	_	_
28-24	2669-2680	β-oxidation	substance[167]	new[167]	_	_
28-25	2681-2682	.	_	_	_	_

#Text=2.2 .
29-1	2683-2686	2.2	abstract	new	_	_
29-2	2687-2688	.	_	_	_	_

#Text=Takeda G-Protein-Coupled Receptor 5 ( TGR5 )
30-1	2689-2695	Takeda	person[169]	new[169]	_	_
30-2	2696-2713	G-Protein-Coupled	person[169]	new[169]	_	_
30-3	2714-2722	Receptor	substance[170]	giv[170]	_	_
30-4	2723-2724	5	substance[170]	giv[170]	_	_
30-5	2725-2726	(	_	_	_	_
30-6	2727-2731	TGR5	abstract	new	coref	31-1
30-7	2732-2733	)	_	_	_	_

#Text=TGR5 is a G-protein coupled membrane receptor that BAs activate .
31-1	2734-2738	TGR5	abstract	giv	coref	31-3[174_0]
31-2	2739-2741	is	_	_	_	_
31-3	2742-2743	a	substance[174]	giv[174]	coref	32-10[178_174]
31-4	2744-2753	G-protein	substance[174]	giv[174]	_	_
31-5	2754-2761	coupled	substance[174]	giv[174]	_	_
31-6	2762-2770	membrane	object|substance[174]	new|giv[174]	_	_
31-7	2771-2779	receptor	substance[174]	giv[174]	_	_
31-8	2780-2784	that	_	_	_	_
31-9	2785-2788	BAs	abstract	giv	coref	32-12[179_0]
31-10	2789-2797	activate	_	_	_	_
31-11	2798-2799	.	_	_	_	_

#Text=LCA is considered to be the strongest activator of TGR5 among the main primary and secondary BAs .
32-1	2800-2803	LCA	place	giv	_	_
32-2	2804-2806	is	_	_	_	_
32-3	2807-2817	considered	_	_	_	_
32-4	2818-2820	to	_	_	_	_
32-5	2821-2823	be	_	_	_	_
32-6	2824-2827	the	object[177]	giv[177]	_	_
32-7	2828-2837	strongest	object[177]	giv[177]	_	_
32-8	2838-2847	activator	object[177]	giv[177]	_	_
32-9	2848-2850	of	object[177]	giv[177]	_	_
32-10	2851-2855	TGR5	object[177]|abstract[178]	giv[177]|giv[178]	coref	35-1[0_178]
32-11	2856-2861	among	object[177]|abstract[178]	giv[177]|giv[178]	_	_
32-12	2862-2865	the	object[177]|abstract[178]|abstract[179]	giv[177]|giv[178]|giv[179]	ana	33-1[0_179]
32-13	2866-2870	main	object[177]|abstract[178]|abstract[179]	giv[177]|giv[178]|giv[179]	_	_
32-14	2871-2878	primary	object[177]|abstract[178]|abstract[179]	giv[177]|giv[178]|giv[179]	_	_
32-15	2879-2882	and	object[177]|abstract[178]|abstract[179]	giv[177]|giv[178]|giv[179]	_	_
32-16	2883-2892	secondary	object[177]|abstract[178]|abstract[179]	giv[177]|giv[178]|giv[179]	_	_
32-17	2893-2896	BAs	object[177]|abstract[178]|abstract[179]	giv[177]|giv[178]|giv[179]	_	_
32-18	2897-2898	.	_	_	_	_

#Text=It is widely expressed in the body , for example in the gallbladder , ileum , colon , liver ( not in hepatocytes though ) , brown adipose tissue ( BAT ) , nervous system , and muscle .
33-1	2899-2901	It	abstract	giv	_	_
33-2	2902-2904	is	_	_	_	_
33-3	2905-2911	widely	_	_	_	_
33-4	2912-2921	expressed	_	_	_	_
33-5	2922-2924	in	_	_	_	_
33-6	2925-2928	the	place[181]	new[181]	_	_
33-7	2929-2933	body	place[181]	new[181]	_	_
33-8	2934-2935	,	_	_	_	_
33-9	2936-2939	for	_	_	_	_
33-10	2940-2947	example	_	_	_	_
33-11	2948-2950	in	_	_	_	_
33-12	2951-2954	the	place[182]	new[182]	_	_
33-13	2955-2966	gallbladder	place[182]	new[182]	_	_
33-14	2967-2968	,	_	_	_	_
33-15	2969-2974	ileum	place	giv	_	_
33-16	2975-2976	,	_	_	_	_
33-17	2977-2982	colon	place	new	_	_
33-18	2983-2984	,	_	_	_	_
33-19	2985-2990	liver	object[185]	giv[185]	_	_
33-20	2991-2992	(	object[185]	giv[185]	_	_
33-21	2993-2996	not	object[185]	giv[185]	_	_
33-22	2997-2999	in	object[185]	giv[185]	_	_
33-23	3000-3011	hepatocytes	object[185]|place[186]	giv[185]|giv[186]	_	_
33-24	3012-3018	though	object[185]|place[186]	giv[185]|giv[186]	_	_
33-25	3019-3020	)	object[185]	giv[185]	_	_
33-26	3021-3022	,	_	_	_	_
33-27	3023-3028	brown	object[188]	new[188]	appos	33-31[0_188]
33-28	3029-3036	adipose	abstract|object[188]	new|new[188]	coref	34-36
33-29	3037-3043	tissue	object[188]	new[188]	_	_
33-30	3044-3045	(	_	_	_	_
33-31	3046-3049	BAT	object	giv	coref	34-25
33-32	3050-3051	)	_	_	_	_
33-33	3052-3053	,	_	_	_	_
33-34	3054-3061	nervous	object[190]	new[190]	_	_
33-35	3062-3068	system	object[190]	new[190]	_	_
33-36	3069-3070	,	_	_	_	_
33-37	3071-3074	and	_	_	_	_
33-38	3075-3081	muscle	object	new	_	_
33-39	3082-3083	.	_	_	_	_

#Text=Besides being involved in BA , glucose , and lipid metabolism , interestingly , it also plays a role in increasing the induction of BAT expression in thermogenesis and energy release via browning of white adipose tissue and .
34-1	3084-3091	Besides	_	_	_	_
34-2	3092-3097	being	_	_	_	_
34-3	3098-3106	involved	_	_	_	_
34-4	3107-3109	in	_	_	_	_
34-5	3110-3112	BA	substance	giv	coref	35-7
34-6	3113-3114	,	_	_	_	_
34-7	3115-3122	glucose	substance	giv	coref	36-28
34-8	3123-3124	,	_	_	_	_
34-9	3125-3128	and	_	_	_	_
34-10	3129-3134	lipid	object|abstract[195]	giv|giv[195]	ana	34-15[0_195]
34-11	3135-3145	metabolism	abstract[195]	giv[195]	_	_
34-12	3146-3147	,	_	_	_	_
34-13	3148-3161	interestingly	_	_	_	_
34-14	3162-3163	,	_	_	_	_
34-15	3164-3166	it	abstract	giv	_	_
34-16	3167-3171	also	_	_	_	_
34-17	3172-3177	plays	_	_	_	_
34-18	3178-3179	a	abstract[197]	giv[197]	_	_
34-19	3180-3184	role	abstract[197]	giv[197]	_	_
34-20	3185-3187	in	_	_	_	_
34-21	3188-3198	increasing	_	_	_	_
34-22	3199-3202	the	abstract[198]	new[198]	_	_
34-23	3203-3212	induction	abstract[198]	new[198]	_	_
34-24	3213-3215	of	abstract[198]	new[198]	_	_
34-25	3216-3219	BAT	abstract[198]|object|abstract[200]	new[198]|giv|giv[200]	_	_
34-26	3220-3230	expression	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
34-27	3231-3233	in	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
34-28	3234-3247	thermogenesis	abstract[198]|abstract[200]|abstract	new[198]|giv[200]|new	_	_
34-29	3248-3251	and	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
34-30	3252-3258	energy	abstract[198]|abstract[200]|substance|abstract[203]	new[198]|giv[200]|new|new[203]	coref	36-34
34-31	3259-3266	release	abstract[198]|abstract[200]|abstract[203]	new[198]|giv[200]|new[203]	_	_
34-32	3267-3270	via	_	_	_	_
34-33	3271-3279	browning	event[204]	new[204]	_	_
34-34	3280-3282	of	event[204]	new[204]	_	_
34-35	3283-3288	white	event[204]|object[206]	new[204]|new[206]	_	_
34-36	3289-3296	adipose	event[204]|abstract|object[206]	new[204]|giv|new[206]	_	_
34-37	3297-3303	tissue	event[204]|object[206]	new[204]|new[206]	_	_
34-38	3304-3307	and	event[204]	new[204]	_	_
34-39	3308-3309	.	_	_	_	_

#Text=TGR5 knockout leads to a changed BA composition and has anti-inflammatory properties by for example by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells ( NF-κB ) or LPS-induced production of inflammatory cytokines in macrophages .
35-1	3310-3314	TGR5	event|abstract[208]	giv|new[208]	coref|coref	36-5|36-6[0_208]
35-2	3315-3323	knockout	abstract[208]	new[208]	_	_
35-3	3324-3329	leads	_	_	_	_
35-4	3330-3332	to	_	_	_	_
35-5	3333-3334	a	abstract[210]	new[210]	_	_
35-6	3335-3342	changed	abstract[210]	new[210]	_	_
35-7	3343-3345	BA	person|abstract[210]	giv|new[210]	_	_
35-8	3346-3357	composition	abstract[210]	new[210]	_	_
35-9	3358-3361	and	_	_	_	_
35-10	3362-3365	has	_	_	_	_
35-11	3366-3383	anti-inflammatory	abstract[211]	new[211]	_	_
35-12	3384-3394	properties	abstract[211]	new[211]	_	_
35-13	3395-3397	by	_	_	_	_
35-14	3398-3401	for	_	_	_	_
35-15	3402-3409	example	_	_	_	_
35-16	3410-3412	by	_	_	_	_
35-17	3413-3423	inhibiting	_	_	_	_
35-18	3424-3431	nuclear	abstract[213]	new[213]	_	_
35-19	3432-3438	factor	abstract|abstract[213]	giv|new[213]	_	_
35-20	3439-3465	kappa-light-chain-enhancer	abstract[213]	new[213]	_	_
35-21	3466-3468	of	abstract[213]	new[213]	_	_
35-22	3469-3478	activated	abstract[213]|abstract[214]	new[213]|new[214]	appos	35-26[0_214]
35-23	3479-3480	B	abstract[213]|abstract[214]	new[213]|new[214]	_	_
35-24	3481-3486	cells	abstract[213]|abstract[214]	new[213]|new[214]	_	_
35-25	3487-3488	(	_	_	_	_
35-26	3489-3494	NF-κB	abstract	giv	_	_
35-27	3495-3496	)	_	_	_	_
35-28	3497-3499	or	_	_	_	_
35-29	3500-3511	LPS-induced	object|abstract[217]	new|new[217]	_	_
35-30	3512-3522	production	abstract[217]	new[217]	_	_
35-31	3523-3525	of	abstract[217]	new[217]	_	_
35-32	3526-3538	inflammatory	abstract[217]|substance[218]	new[217]|new[218]	_	_
35-33	3539-3548	cytokines	abstract[217]|substance[218]	new[217]|new[218]	_	_
35-34	3549-3551	in	abstract[217]|substance[218]	new[217]|new[218]	_	_
35-35	3552-3563	macrophages	abstract[217]|substance[218]|object	new[217]|new[218]|new	_	_
35-36	3564-3565	.	_	_	_	_

#Text=In another experiment , TGR5 knockout mice received a sleeve gastrectomy and it was shown how TGR5 is important in order to decrease hepatic steatosis , improve glucose control , and increase the energy expenditure post-surgery .
36-1	3566-3568	In	_	_	_	_
36-2	3569-3576	another	abstract[220]	new[220]	ana	36-13[0_220]
36-3	3577-3587	experiment	abstract[220]	new[220]	_	_
36-4	3588-3589	,	_	_	_	_
36-5	3590-3594	TGR5	animal|animal[223]	giv|giv[223]	coref	36-17
36-6	3595-3603	knockout	abstract|animal[223]	giv|giv[223]	_	_
36-7	3604-3608	mice	animal[223]	giv[223]	_	_
36-8	3609-3617	received	_	_	_	_
36-9	3618-3619	a	object[225]	new[225]	_	_
36-10	3620-3626	sleeve	object|object[225]	new|new[225]	_	_
36-11	3627-3638	gastrectomy	object[225]	new[225]	_	_
36-12	3639-3642	and	_	_	_	_
36-13	3643-3645	it	abstract	giv	_	_
36-14	3646-3649	was	_	_	_	_
36-15	3650-3655	shown	_	_	_	_
36-16	3656-3659	how	_	_	_	_
36-17	3660-3664	TGR5	abstract	giv	_	_
36-18	3665-3667	is	_	_	_	_
36-19	3668-3677	important	_	_	_	_
36-20	3678-3680	in	_	_	_	_
36-21	3681-3686	order	_	_	_	_
36-22	3687-3689	to	_	_	_	_
36-23	3690-3698	decrease	_	_	_	_
36-24	3699-3706	hepatic	abstract|abstract[229]	giv|giv[229]	_	_
36-25	3707-3716	steatosis	abstract[229]	giv[229]	_	_
36-26	3717-3718	,	_	_	_	_
36-27	3719-3726	improve	_	_	_	_
36-28	3727-3734	glucose	substance|abstract[231]	giv|new[231]	_	_
36-29	3735-3742	control	abstract[231]	new[231]	_	_
36-30	3743-3744	,	_	_	_	_
36-31	3745-3748	and	_	_	_	_
36-32	3749-3757	increase	_	_	_	_
36-33	3758-3761	the	_	_	_	_
36-34	3762-3768	energy	abstract	giv	_	_
36-35	3769-3780	expenditure	abstract	new	_	_
36-36	3781-3793	post-surgery	_	_	_	_
36-37	3794-3795	.	_	_	_	_
